IGF-1 (Insulin-like Growth Factor 1) is a hormone that plays a crucial role in growth and metabolism, with evidence suggesting its potential for preventing severe retinopathy in premature infants and sustained elevation in Growth Hormone Deficiency (GHD) treatment. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist, meaning it stimulates the body's own production of growth hormone. Studies in our corpus indicate Ipamorelin's potential in accelerating gastrointestinal recovery after bowel surgery and its selective action in boosting growth hormone, muscle, and bone without significantly impacting cortisol or prolactin.
| IGF-1 | Ipamorelin | |
|---|---|---|
| Drug class | growth factor | ghrh secretagogue, ghrelin mimetic |
| Studies in corpus | 108 | 45 |
| Highest evidence tier | meta analysis | rct |
| Evidence tier mix | cohort · 5 rct · 22 other · 27 case series · 1 meta analysis · 2 case report · 2 review · 12 preclinical animal · 27 in vitro · 6 | other · 12 preclinical animal · 22 rct · 4 in vitro · 5 review · 1 |
| Studies with explicit sample size | 10 | 3 |
| Head-to-head studies in corpus | 3 | |
Studies in our corpus that mention both IGF-1 and Ipamorelin — the gold-standard direct comparison evidence.
These findings suggest that Ipamorelin could be a promising therapeutic agent for conditions characterized by growth hormone deficiency, sarcopenia, or osteoporosis. Its selective action as a growth hormone secretagogue receptor (GHSR) agonist, without sign…
This study highlights a critical paradox in diabetes: GH hypersecretion coexisting with peripheral GH receptor resistance. This finding suggests that the body attempts to compensate for impaired GH signaling by increasing GH production, but target tissues r…
This study unequivocally highlights the severe public health risks associated with the use of unregulated black market growth-promoting products. Consumers are frequently exposed to mislabeled, contaminated, or entirely fraudulent substances, leading to unp…
No direct head-to-head trials in our corpus. Indirect comparison only. IGF-1 is a direct growth factor, with studies exploring its role in linking birth size to infant metabolic health, and as a potential treatment for Rett Syndrome. An oral SSTR5 antagonist has been shown to sustain IGF-1 elevation in a Phase 1 trial for GHD. Ipamorelin, conversely, acts as a GHSR agonist, stimulating the pituitary to release growth hormone. Preclinical animal studies suggest Ipamorelin could be a promising therapeutic for conditions like sarcopenia or osteoporosis due to its selective GH-releasing action. Human trials have mapped Ipamorelin's growth hormone release profile and shown its efficacy in reducing postoperative ileus, leading to shorter hospital stays. While IGF-1 has been investigated in meta-analyses and Phase 2 trials, Ipamorelin's efficacy in accelerating bowel recovery after surgery has been observed in RCTs.
Looking for vendor-level purity, endotoxin, and HPLC data on IGF-1 or Ipamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.